Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

IACOBONI, GLORIA; CABALLERO GONZÁLEZ, ANA CAROLINA; Delgado Serrano, Javier; BASTOS, MARIANA; Martínez-Cibrian, Nuria; Barba, Pere; Navarro Garces, Victor

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	IACOBONI, GLORIA
dc.contributor.author	CABALLERO GONZÁLEZ, ANA CAROLINA
dc.contributor.author	Delgado Serrano, Javier
dc.contributor.author	BASTOS, MARIANA
dc.contributor.author	Martínez-Cibrian, Nuria
dc.contributor.author	Barba, Pere
dc.contributor.author	Navarro Garces, Victor
dc.date.accessioned	2025-03-19T11:45:27Z
dc.date.available	2025-03-19T11:45:27Z
dc.date.issued	2025-02-04
dc.identifier.citation	Bastos-Oreiro M, Iacoboni G, Garcés VN, Caballero AC, Martínez N, Delgado J, et al. Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study. HemaSphere. 2025 Feb;9(2):e70077.
dc.identifier.issn	2572-9241
dc.identifier.uri	http://hdl.handle.net/11351/12787
dc.description	Terapia de células T; Linfoma de células B grandes; Progresión de la enfermedad
dc.language.iso	eng
dc.publisher	Wiley
dc.relation.ispartofseries	HemaSphere;9(2)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Avaluació de resultats (Assistència sanitària)
dc.subject	Cèl·lules B - Tumors - Immunoteràpia
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Lymphoma, Large B-Cell, Diffuse
dc.subject.mesh	/drug therapy
dc.subject.mesh	Disease Progression
dc.subject.mesh	Immunotherapy, Adoptive
dc.title	Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1002/hem3.70077
dc.subject.decs	resultado del tratamiento
dc.subject.decs	linfoma de células B grandes difuso
dc.subject.decs	/farmacoterapia
dc.subject.decs	progresión de la enfermedad
dc.subject.decs	inmunoterapia adoptiva
dc.relation.publishversion	https://doi.org/10.1002/hem3.70077
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Bastos‐Oreiro M] Hematology Department, Hospital General Universitario Gregorio Marañon, Instituto de investigación sanitaria Gregorio Marañon, Madrid, Spain. [Iacoboni G] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Garcés VN, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Caballero AC] Department d’hematologia, Hospital Sant Pau, Barcelona, Spain. [Martínez N] Servei d'Hematologia, Hospital Clínic, Barcelona, Spain. [Delgado J] Hematology Department, Virgen del Rocío, Sevilla, Spain
dc.identifier.pmid	39906687
dc.identifier.wos	001413884400001
dc.rights.accessrights	info:eu-repo/semantics/openAccess